BACKGROUND: Coolmine’s implementation of quality standards involves a period of change management, strategic planning, and national policy development. METHODS: A narrative case study focusing on national policy and internal strategic planning. CONCLUSIONS: From 2000, Coolmine embarked on a change management journey that kept the organisation at the forefront of drug and alcohol treatment in Ireland and internationally while maintaining fidelity to the Therapeutic Community. The strategy for quality assurance is replicable across similar organisations
In clinical practice, there is considerable variation in the timing of the initiation of maintenance dialysis for patients with stage V chronic kidney disease, with a worldwide trend toward early initiation. In this study, conducted at 32 centers in Australia and New Zealand, we examined whether the timing of the initiation of maintenance dialysis influenced survival among patients with chronic kidney disease. METHODS: We randomly assigned patients 18 years of age or older with progressive chronic kidney disease and an estimated glomerular filtration rate (GFR) between 10.0 and 15.0 ml per minute per 1.73 m2 of body-surface area (calculated with the use of the Cockcroft-Gault equation) to planned initiation of dialysis when the estimated GFR was 10.0 to 14.0 ml per minute (early start) or when the estimated GFR was 5.0 to 7.0 ml per minute (late start). The primary outcome was death from any cause. RESULTS: Between July 2000 and November 2008, a total of 828 adults (mean age, 60.4 years; 542 men and 286 women; 355 with diabetes) underwent randomization, with a median time to the initiation of dialysis of 1.80 months (95% confidence interval [CI], 1.60 to 2.23) in the early-start group and 7.40 months (95% CI, 6.23 to 8.27) in the late-start group. A total of 75.9% of the patients in the late-start group initiated dialysis when the estimated GFR was above the target of 7.0 ml per minute, owing to the development of symptoms. During a median follow-up period of 3.59 years, 152 of 404 patients in the early-start group (37.6%) and 155 of 424 in the late-start group (36.6%) died (hazard ratio with early initiation, 1.04; 95% CI, 0.83 to 1.30; P=0.75). There was no significant difference between the groups in the frequency of adverse events (cardiovascular events, infections, or complications of dialysis). CONCLUSIONS: In this study, planned early initiation of dialysis in patients with stage V chronic kidney disease was not associated with an improvement in survival or clinical outcomes. (Funded by the National Health and Medical Research Council of Australia and others; Australian New Zealand Clinical Trials Registry number, 12609000266268.)
- MeSH
- časové faktory MeSH
- chronické selhání ledvin komplikace mortalita terapie MeSH
- dialýza ledvin metody škodlivé účinky MeSH
- dospělí MeSH
- financování organizované MeSH
- hodnoty glomerulární filtrace MeSH
- infekce etiologie mortalita MeSH
- Kaplanův-Meierův odhad MeSH
- kardiovaskulární nemoci etiologie mortalita MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- proporcionální rizikové modely MeSH
- randomizované kontrolované studie jako téma MeSH
- uremie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- multicentrická studie MeSH
- MeSH
- antibakteriální látky MeSH
- bronchitida diagnóza farmakoterapie MeSH
- faryngitida diagnóza farmakoterapie MeSH
- infekce dýchací soustavy diagnóza farmakoterapie MeSH
- infekce získané v komunitě diagnóza farmakoterapie MeSH
- lidé MeSH
- otitida diagnóza farmakoterapie MeSH
- sinusitida diagnóza farmakoterapie MeSH
- Check Tag
- lidé MeSH
- MeSH
- bronchitida terapie MeSH
- cefaklor farmakologie MeSH
- cefuroxim farmakologie MeSH
- dospělí MeSH
- lidé MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- srovnávací studie MeSH
Gut ; Supplement Vol. 35. 3
[1st ed.] S27 s. : tab., grafy ; 28 cm
- MeSH
- gastrointestinální nemoci farmakoterapie MeSH
- somatostatin farmakologie analogy a deriváty MeSH
- trávicí systém - fyziologické jevy MeSH
- trávicí systém účinky léků MeSH
- Publikační typ
- kongresy MeSH
- sborníky MeSH
- Konspekt
- Lékařské vědy. Lékařství
- NLK Obory
- gastroenterologie
- farmacie a farmakologie
- MeSH
- alely MeSH
- cystická fibróza MeSH
- DNA MeSH
- lidé MeSH
- prenatální diagnóza MeSH
- těhotenství MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH